Saxagliptin: A new dipeptidyl peptidase 4 inhibitor for type 2 diabetes

Annals of Pharmacotherapy

Volumn 44, Issue 6, 2010, Pages 1046-1053

  Borja Hart, Nancy L ^a   Whalen, Karen L ^b  

^a NOVA SOUTHEASTERN UNIVERSITY   (United States)

^b UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

BMS 477118; Diabetes; DPP 4 inhibitors; Onglyza; Saxagliptin

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLITAZONE DERIVATIVE; GLUCAGON; GLUCOSE; HEMOGLOBIN A1C; INCRETIN; INSULIN; METFORMIN; SAXAGLIPTIN; SULFONYLUREA DERIVATIVE;

ADD ON THERAPY; ARTHRALGIA; BACKACHE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COUGHING; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG ACTIVITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DYSPEPSIA; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HEADACHE; HEART DISEASE; HUMAN; HYPERTENSION; HYPOGLYCEMIA; INFLUENZA; INSULIN RELEASE; LIMB PAIN; LOW DRUG DOSE; LYMPHOCYTOPENIA; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL EDEMA; PRIORITY JOURNAL; REVIEW; RHINOPHARYNGITIS; SINUSITIS; SKIN DISEASE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

ADAMANTANE; ANIMALS; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; DIPEPTIDES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HEADACHE; HUMANS; RESPIRATORY TRACT INFECTIONS;

EID: 77952911388     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1P003     Document Type: Review

References (26)

1. American Diabetes Association. Diabetes basics: diabetes statistics. www. diabetes.org (accessed 2009 Sept 2).
2. American Diabetes Association. Standards of medical care in diabetes-2010. Diabetes Care 2010;33(suppl):S11-61. DOI 10.2337/dc10-S011
3. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2009;32:193-203. DOI 10.2337/dc08-9025
4. U.S. Food and Drug Administration. FDA approves new drug treatment for type 2 diabetes. www.fda.gov (accessed 2009 Sept 2).
5. Product information. Onglyza (saxagliptin). Princeton, NJ, and Wilmington, DE: Bristol-Myers Squibb Company and AstraZeneca Pharmaceuticals LP, July 2009.
6. Deacon CF, Holst JJ. Saxagliptin: a new dipeptidyl peptidase- 4 inhibitor for the treatment of type 2 diabetes. Adv Ther 2009;26:488-499 DOI 10.1007/s12325-009-0030-9
7. Tahrani AA, Piya MK, Barnett AH. Saxagliptin: a new DPP- 4 inhibitor for the treatment of type 2 diabetes mellitus. Adv Ther 2009;26:249-262 DOI 10.1007/s12325-009-0014-9
8. Fura A, Khanna A, Vyas V, et al. Pharmacokinetics of the dipeptidyl peptidase 4 inhibitor saxagliptin in rats, dogs, and monkeys and clinical projections. Drug Metab Dispos 2009;37:1164-1171 DOI 10.1124/dmd.108.0260889.
9. Dhillon S, Weber J. Saxagliptin. Drugs 2009;69:2103-2114 DOI 10.2165/11201170-000000000-00000
10. Boulton DW, Geraldes M. Safety, tolerability, pharmacokinetics and pharmacodynamics of once-daily oral doses of saxagliptin for 2 weeks in type 2 diabetic and healthy subjects (abstract 606-P plus poster). Presented at: 67th Scientific Sessions, American Diabetes Association Annual Meeting, Chicago, IL, June 22-26, 2007.
11. Boulton DW, Li L, Patel CG, et al. No pharmacokinetic interaction between saxagliptin and digoxin in healthy subjects (abstract PIII-69). Clin Pharmacol Ther 2008;83(suppl):S93.
12. Girgis S, Patel CG, Li L, et al. Effect of diltiazem on the pharmacokinetics of saxagliptin in healthy subjects (abstract 72). J Clin Pharmacol 2007;47:1199.
13. Boulton DW, Brenner E, Royzman K, Li L. Effect of ketoconazole on the pharmacokinetics of saxagliptin in healthy subjects (abstract 89). J Clin Pharmacol 2007;47:1203.
14. Girgis S, You X, Li L, Maurer C, Whigan D, Boulton DW. The effect of simvastatin on the pharmacokinetics of saxagliptin in healthy subjects (abstract 28). J Clin Pharmacol 2007;47:1188.
15. Boulton DW, Adams D, Li L, et al. Magnesium and aluminum hydroxides plus simethicone, famotidine, or omeprazole do not meaningfully affect the pharmacokinetics of saxagliptin in healthy subjects (abstract PIII-68). Clin Pharmacol Ther 2008;83(suppl):S92-3.
16. Rosenstock J, Sankoh S, List JF. Glucose-lowering activity of the dipeptidyl peptidase- 4 inhibitor saxagliptin in drug-naïve patients with type 2 diabetes. Diabetes Obes Metab 2008;10:376-386 DOI 10.1111/j.1463-1326. 2008.00876.x
17. Rosenstock J, Aguilar-Salinas C, Klein E, Nepal S, List J, Chen R; CV181-011 Study Investigators. Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes. Curr Med Res Opin 2009;25:2401-2411 DOI 10.1185/03007990903178735
18. Jadzinsky M, Pfützner A, Paz-Pacheco E, Xu Z, Allen E, Chen R; CV181-039 Investigators. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab 2009;11:611-622 DOI 10.1111/j.1463-1326.2009.01056.x
19. DeFronzo RA, Hissa MN, Garber AJ, Gross JL, et al.; Saxagliptin 014 Study Group. The efficacy and safety of saxagliptin when added to met-formin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care 2009;32:1649-1655 DOI 10.2337/dc08-1984
20. Chacra AR, Tan GH, Apanovitch A, Ravichandran S, List J, Chen R; CV181-040 Investigators. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial. Int J Clin Pract 2009;63:1395-1406 DOI 10.1111/j.1742-1241.2009.02143.x
21. Hollander P, Li J, Allen E, Chen R; for the CV181-013 Investigators. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. J Clin Endocrinol Metab. 2009;94:180-189 DOI 10.1210/jc.2009-0550
22. Defronzo RA, Hissa MN, Garber AJ, et al. Once-daily saxagliptin added to metformin provides sustained glycemic control and is well tolerated over 102 weeks in patients with T2D (abstract 547-P). Presented at: 69th Scientific Sessions, American Diabetes Association Annual Meeting, New Orleans, LA, June 5-9, 2009.
23. Product information. Januvia (sitagliptin). Whitehouse Station, NJ: Merck & Co., Inc.; December 2009.
24. FDA U.S. Food and Drug Administration. Information for healthcare professionals-acute pancreatitis and sitagliptin (marketed as Januvia and Janumet). www.fda.gov (accessed 2010 Feb 11).
25. Supply Management Online. supply.mckesson.com (accessed 2009 Dec 21).
26. ClinicalTrials.gov. www.clinicaltrials.gov (accessed 2009 Sept 28).